-
Jefferies Comments On Gilead Sciences 1Q11 Results
Thursday, April 21, 2011 - 8:22am | 90According to Jefferies, Gilead Sciences (NASDAQ: GILD) reported 1Q11 earnings that fell below its and Street expectations, with shortfalls in both the U.S. and Europe. Jefferies said that the company believes that underlying demand for its HIV drugs in both geographies are strong, and provided a...
-
Benzinga's Top Pre-Market NASDAQ Gainers (TRAD, BIIB, FFIV, OREX)
Thursday, April 21, 2011 - 8:10am | 135TradeStation Group Inc (NASDAQ: TRAD) shares surged 31.31% to $9.73 in the pre-market session. Monex Group announced its plans to acquire TRAD for around $411 million. Biogen Idec Inc (NASDAQ: BIIB) shares advanced 15.47% to $99.96 in the pre-market session. BIIB reported upbeat Q1 results. F5...
-
J.P. Morgan Maintains Overweight on Gilead Sciences (GILD)
Thursday, April 21, 2011 - 7:56am | 144J.P. Morgan is out with its report today on Gilead Sciences (NASDAQ: GILD), maintaining Overweight. In a note to clients, J.P. Morgan writes, "Overall, we found 1Q results disappointing with uncertainty around the HIV business. That said, there are major pipeline events that are less than three...
-
UPDATE: Piper Jaffray Raises PT on Cepheid to $33 (CPHD)
Thursday, April 21, 2011 - 7:52am | 125Piper Jaffray is out with its report today on Cepheid (NASDAQ: CPHD), raising its PT from $29 to $33. In a note to clients, Piper Jaffray writes, "Cepheid reported 1Q11 results above our and Street consensus expectations, with both revenue and EPS ahead of our estimates. Instrument revenue ($12.7M...
-
Piper Jaffray Reports Mixed 1Q Earnings For Amgen
Thursday, April 21, 2011 - 7:49am | 137According to Piper Jaffray, Amgen (NASDAQ: AMGN) 1Q earnings are mixed. Piper Jaffray said that it remains buyers of AMGN after a mixed 1Q11 earnings report, which featured strong Xgeva sales offset by weak Prolia and Epogen sales. “1Q11 confirmed our expectation for a more modest market...
-
Citigroup Raises PT On Gilead Sciences To $44
Thursday, April 21, 2011 - 7:40am | 26Citigroup has raised the price target on Gilead Sciences (NASDAQ: GILD) from $43 to $44 and maintains its Hold rating.
-
AVI BioPharma Reports Modification of Contract; Funding Reduced to $13.1M (AVII)
Thursday, April 21, 2011 - 7:16am | 20AVI BioPharma Reports Modification of Contract; Funding Reduced to $13.1M (NASDAQ: AVII)
-
Jefferies Raises PT On Cepheid To $35
Thursday, April 21, 2011 - 7:04am | 26Jefferies & Company has raised the price target on Cepheid (NASDAQ: CPHD) from $30 to $35 and maintains its Buy rating.
-
Alexion Reports First Quarter 2011 Results
Thursday, April 21, 2011 - 7:01am | 52Alexion Pharmaceuticals (NASDAQ: ALXN) today announced financial results for the three months ended March 31, 2011. Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $166.1 million, reflecting steady additions of new patients,...
-
Biogen Idec Reports First Quarter 2011 Results
Thursday, April 21, 2011 - 6:59am | 236Biogen Idec (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2011 results. First Quarter 2011 Highlights: First quarter revenues were $1.2 billion, an increase of 9% versus...
-
Piper Jaffray Raises PT On Cepheid To $33
Thursday, April 21, 2011 - 6:41am | 26Piper Jaffray has raised the price target on Cepheid (NASDAQ: CPHD) from $29 to $33 and maintains its Overweight rating.
-
Top Trade Ideas for Thursday, April 21
Thursday, April 21, 2011 - 6:27am | 2954( click to enlarge ) Good morning everyone. When I mentioned ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Monday the stock had just breached the triangle's resistance around $1.90 and yesterday it closed at $2.19. This jump has also helped the stock breach its immediate resistance level of $...
-
Piper Jaffray Lowers PT On Amgen To $72
Thursday, April 21, 2011 - 6:06am | 26Piper Jaffray has lowered the price target on Amgen (NASDAQ: AMGN) from $73 to $72 and maintains its Overweight rating.
-
Head and Shoulders 04-20-2011
Wednesday, April 20, 2011 - 5:32pm | 792Cusick's Corner The markets into the afternoon could not muster much of a push after today's impressive open. The S&P did chop along in a tight range, this is notable because I do not want to see a market that makes a move and then starts to look over its shoulders. I use the term shoulders...
-
Celera Provides Update on Recent Scientific Findings on KIF6 and PMA Application
Wednesday, April 20, 2011 - 4:21pm | 157Celera Corporation (NASDAQ: CRA) today provided an update on recent scientific findings pertaining to the KIF6 gene variant and its pre-market approval application (PMA) with the United States Food and Drug Administration (FDA) for its KIF6 Genotyping Assay. In nine previously published peer-...